Patents Assigned to DENALI THERAPEUTICS, INC.
  • Compounds, compositions and methods
    Patent number: 9815850
    Abstract: The present disclosure relates generally to compounds and compositions, and their use as kinase inhibitors.
    Type: Grant
    Filed: February 3, 2017
    Date of Patent: November 14, 2017
    Assignee: Denali Therapeutics Inc.
    Inventors: Anthony A. Estrada, Jianwen A. Feng, Brian Fox, Colin Philip Leslie, Joseph P. Lyssikatos, Alfonso Pozzan, Zachary K. Sweeney, Javier de Vicente Fidalgo
  • Oxadiazine compounds and methods of use thereof
    Patent number: 9802927
    Abstract: The present disclosure relates to oxadiazine compounds, pharmaceutical compositions comprising an effective amount of an oxadiazine compound and methods for using an oxadiazine compound in the treatment of a neurodegenerative disease, comprising administering to a subject in need thereof an effective amount of an oxadiazine compound.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: October 31, 2017
    Assignee: DENALI THERAPEUTICS, INC.
    Inventors: Raksha Acharya, Duane A. Burnett, Matthew Gregory Bursavich, Andrew Simon Cook, Bryce Alden Harrison, Andrew J. McRiner
  • Fused morpholinopyrimidines and methods of use thereof
    Patent number: 9771378
    Abstract: The present disclosure relates to Fused Morpholinopyrimidines, pharmaceutical compositions comprising an effective amount of a Fused Morpholinopyrimidine and methods for using a Fused Morpholinopyrimidine in the treatment of a neurodegenerative disease, comprising administering to a subject in need thereof an effective amount of a Fused Morpholinopyrimidine.
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: September 26, 2017
    Assignee: DENALI THERAPEUTICS, INC.
    Inventors: Duane A. Burnett, Matthew Gregory Bursavich, Andrew J. McRiner